Edition:
United States

Neptune Technologies & Bioressources Inc (NEPT.PH)

NEPT.PH on Philadelphia Stock Exchange

1.10USD
3:58pm EDT
Change (% chg)

$0.01 (+1.39%)
Prev Close
$1.08
Open
$1.09
Day's High
$1.10
Day's Low
$1.09
Volume
850
Avg. Vol
600
52-wk High
$1.50
52-wk Low
$0.95

Latest Key Developments (Source: Significant Developments)

Neptune enters commercial distribution joint venture in China with Shanghai Chonghe Marine Industry
Wednesday, 5 Apr 2017 05:00pm EDT 

Neptune Technologies & Bioressources Inc : Neptune enters into commercial distribution joint venture in China with Shanghai Chonghe Marine Industry Co Ltd . Neptune Technologies & Bioressources Inc - shipments of krill oil under joint venture are projected to start in Q1 ending June 30, 2017 .Neptune Technologies & Bioressources Inc - under agreement, Neptune will own a 30 pct interest in joint venture while CMI/Sunline fishery will hold 70 pct.  Full Article

Neptune, Enzymotec reach patent agreement ending all litigation
Monday, 3 Apr 2017 08:00am EDT 

Enzymotec Ltd : Neptune and Enzymotec reach patent agreement ending all litigation . Enzymotec Ltd - Enzymotec to make a one-time payment of us$1.63 million to Neptune . Enzymotec Ltd - Enzymotec grants Neptune a worldwide and royalty-free license to its krill-related patents . Enzymotec Ltd - Neptune extends Enzymotec's worldwide and royalty-free license to its krill-related patents .Enzymotec Ltd - co, Neptune Technologies entered into broad patent cross-licensing agreement, which ends all outstanding litigation between companies.  Full Article

Acasti Pharma announces pricing for its public offering of units
Friday, 10 Feb 2017 04:26pm EST 

Acasti Pharma Inc : Acasti Pharma announces pricing for its public offering of units .Acasti Pharma- entered agency agreement with Echelon Wealth Partners as sole bookrunner, lead agent; agent to offer units for proceeds of C$4.5 million-C$8 million.  Full Article

Neptune to buy 2.4 pct stake in Bluehole
Tuesday, 31 Jan 2017 02:58am EST 

Neptune Company <217270.KQ> : Says it will buy 166,666 shares in Bluehole, which is engaged in online and mobile game development, to secure strategic partnership . Says transaction amount is 5 billion won .Says it will hold 2.4 percent stake(166,666 shares) in Bluehole after the transaction.  Full Article

Acasti Pharma Q3 loss C$0.22/shr
Thursday, 12 Jan 2017 05:15pm EST 

Acasti Pharma Inc : Acasti Pharma reports third quarter 2017 financial results . Q3 loss per share C$0.22 . Acasti pharma - Had cash,short-term investments of $5.8 million as of Nov 30, 2016 .Acasti Pharma - if co doesn't raise additional funds, there exists material uncertainty casting substantial doubt about ability to continue as going concern.  Full Article

Acasti Pharma announces proposed offering of units
Monday, 5 Dec 2016 05:38pm EST 

Acasti Pharma Inc : Acasti Pharma announces proposed offering of units .Acasti Pharma-Received receipt for a preliminary short form prospectus for minimum gross proceeds of CAD$6.5 million, maximum gross proceeds of CAD$10 million.  Full Article

Enzymotec qtrly non-gaap earnings per share $0.03
Wednesday, 16 Nov 2016 07:30am EST 

Enzymotec Ltd : Enzymotec - Qtrly net revenues decreased 8.2% and 2.7% to $11.4 million, compared to Q3 of 2015 and Q2 of 2016, respectively . Enzymotec Ltd. reports third quarter 2016 unaudited financial results . Q3 non-gaap earnings per share $0.03 . Q3 gaap loss per share $0.01 . Q3 earnings per share view $0.07 -- Thomson Reuters I/B/E/S . Sees FY 2016 non-gaap earnings per share $0.17 to $0.19 . Sees FY 2016 revenue $47.5 million to $49.5 million . Enzymotec-On April 27, 2014,Neptune Technologies & Bioresources,Co entered into settlement agreement under which all civil actions against co dismissed .On November 2, 2016, Neptune sent company a notice of default and termination in respect of settlement agreement.  Full Article

Neptune and Ingenutra signs exclusive worldwide agreement for MaxSimil
Friday, 7 Oct 2016 08:07am EDT 

Neptune Technologies & Bioressources Inc : Terms also cover potential collaboration between both companies on clinical trials . Neptune Technologies & Bioressources Inc says all other terms of agreement remain confidential . Neptune and Ingenutra sign an exclusive worldwide agreement for Maxsimil . All other terms of agreement remain confidential. . Agreement allows neptune to manufacture, distribute and sell Maxsimil in nutraceutical field worldwide .Says agreement is valid till 2028.  Full Article

Richard Schottenfeld reports 5.4 pct stake in Neptune Technologies & Bioressources
Friday, 22 Jul 2016 04:10pm EDT 

Neptune Technologies & Bioressources Inc : Richard Schottenfeld Reports 5.4 Pct Stake In Neptune Technologies & Bioressources Inc As Of July 12 - SEC filing .Acquired shares of Neptune Technologies common stock believing that such shares of common stock were undervalued.  Full Article

Acasti posts qtrly loss per share of $0.29
Monday, 11 Jul 2016 05:30pm EDT 

Acasti Pharma Inc: Acasti announces first quarter results .Qtrly loss per share $0.29.  Full Article

More From Around the Web